Neurontin (Gabapentin)

Gabapentin binds to the α2δ subunit of voltage‑gated calcium channels in the central nervous system. This binding limits calcium entry into neurons during depolarization, which in turn decreases the release of excitatory neurotransmitters such as glutamate and substance P, reducing neuronal hyperexcitability associated with seizures and pain.

The appropriate dose of Neurontin is individualized by a qualified prescriber based on the specific indication, patient age, renal function, and response to therapy. Healthcare professionals determine the starting dose and any subsequent titration to achieve optimal therapeutic effect while minimizing adverse reactions.

The safety of gabapentin in pregnancy has not been definitively established, and it is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies the potential risk to the fetus. Limited data are available for breastfeeding; a prescriber should evaluate the risk‑benefit ratio before use.

To place an order, submit an enquiry on the Neurontin product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements if applicable) and necessary import documentation.

Compared with other anticonvulsants, gabapentin has a distinct mechanism targeting the α2δ calcium‑channel subunit, which can be advantageous for patients who do not respond to sodium‑channel blockers. It is generally well‑tolerated but may cause more sedation and peripheral edema than some alternatives. Choice of therapy depends on seizure type, comorbid conditions, and individual tolerability.

Neurontin tablets should be stored at ambient temperature, below 25 °C (77 °F). Keep them in the original packaging to protect from moisture and light, and store out of reach of children. Do not refrigerate or freeze the product.

Neurontin is taken orally, usually with or without food, as directed by the prescribing clinician. Tablets should be swallowed whole with a glass of water. The dosing schedule (once, twice, or three times daily) is individualized based on the condition being treated and patient response.

Serious risks include severe skin reactions such as Stevens‑Johnson syndrome, suicidal thoughts or behaviors, anaphylaxis, and blood disorders like agranulocytosis. Patients should be instructed to seek immediate medical attention if they notice rash, mood changes, difficulty breathing, or signs of infection.

Neurontin is contraindicated in patients with known hypersensitivity to gabapentin or any of the tablet excipients. Caution is advised for individuals with severe renal impairment, as the drug is eliminated unchanged by the kidneys, and for pregnant or breastfeeding women unless the potential benefit outweighs the risk.